CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trialsПодробнее

CLL2-GIVe trial: investigating chemotherapy-free treatment of CLLПодробнее

Testing for IgHV and TP53 mutations to guide treatment decisions in CLLПодробнее

Triple combination therapy in CLLПодробнее

Achieving undetectable MRD with ibrutinib plus venetoclax for CLLПодробнее

GLOW: Assessing ibrutinib plus venetoclax in CLLПодробнее

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclaxПодробнее

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022Подробнее

The SYMPATICO trial: ibrutinib plus venetoclax in TP53-mutated MCLПодробнее

Overview of the CLL2-BIG trial of ibrutinib and obinutuzumabПодробнее

Ibrutinib Plus Venetoclax as a Treatment Option for CLLПодробнее

ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patientsПодробнее

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLLПодробнее

The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLLПодробнее

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLLПодробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

Updates from the CLL14 and CLL2-GiVe trials on CLLПодробнее

Ibrutinib + Venetoclax for CLLПодробнее